A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women
单位：[1]Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China[2]Peking Union Med Coll Hosp, Beijing, Peoples R China[3]Peking Univ, Hosp 1, Beijing, Peoples R China[4]China Japan Friendship Hosp, Beijing, Peoples R China[5]Peking Univ, Hosp 3, Beijing, Peoples R China[6]Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China[7]Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China[8]Changhai Hosp Shanghai, Shanghai, Peoples R China[9]Chengdu Matern & Child Care Hosp, Chengdu, Peoples R China[10]Jinan Matern & Child Care Hosp, Jinan, Peoples R China[11]Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China[12]Xinjiang Med Univ, Coll Pharm, Urumqi 830054, Xinjiang, Peoples R China
Aim In a randomized, multicenter, open, controlled trial, we compared the effects of Honglilai Vaginal Cream and Premarin Vaginal Cream in different age subgroups and menopausal year subgroups (trial registration numbers: 02003L00493). Methods Postmenopausal women with Genitourinary Syndrome of Menopause (GSM) were divided into Honglilai group (n = 319) and Premarin group (n = 116), while subgroups were divided according to their different characteristics of age and menopausal years. Honglilai Vaginal Cream (0.625 mg/g) or Premarin Vaginal Cream (0.625 mg/g) once daily for 3 weeks. Results In the subgroup of participates >60 years, there were no significant differences of Vaginal Cell Maturation Index (VMI) between the two groups after treatment (p = .171). In the subgroup of 50-59 years, the VMI of Honglilai group was significantly lower than Premarin group (Honglilai group: 74.37 +/- 22.76; Premarin group: 80.06 +/- 16.15; p = .02). There were no significant differences of Vaginal symptom scores between Honglilai group and Premarin group in every sub-group (p > .05). Conclusions Honglilai Vaginal Cream had comparable efficacy with Premarin Vaginal Cream in Chinese women older than 60 years.
基金：
Beijing Hospitals Authority Clinical
Medicine Development of Special Funding Support (Code: ZYLX202112),
the Major Science and Technology Projects of the Xinjiang Uygur
Autonomous Region (Code: 2017A01002-4).
第一作者单位：[1]Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
通讯作者：
通讯机构：[1]Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China[12]Xinjiang Med Univ, Coll Pharm, Urumqi 830054, Xinjiang, Peoples R China[*1]College of Pharmacy, Xinjiang Medical University, Xinjiang 830054, China[*2]Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
推荐引用方式(GB/T 7714)：
Yang Mukun,Lin Shouqing,Zheng Shurong,et al.A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women[J].GYNECOLOGICAL ENDOCRINOLOGY.2022,doi:10.1080/09513590.2022.2118710.
APA：
Yang, Mukun,Lin, Shouqing,Zheng, Shurong,Sun, Aijun,Bian, Meilu...&Bai, Wenpei.(2022).A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women.GYNECOLOGICAL ENDOCRINOLOGY,,
MLA：
Yang, Mukun,et al."A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women".GYNECOLOGICAL ENDOCRINOLOGY .(2022)
